Insulin resistance (IR) is a central driver of obesity, type 2 diabetes mellitus, and cardiometabolic disease, disproportionately affecting African American (AA) populations who experience higher rates of metabolic complications and mortality. This review synthesizes contemporary evidence on lifestyle, pharmacologic, and emerging biologic strategies to reverse or attenuate IR, with emphasis on population-specific applicability. Sustained caloric restriction and structured physical activity remain foundational, particularly when delivered through intensive behavioral programs shown to be effective in AA cohorts. Pharmacotherapies including metformin, thiazolidinediones, SGLT2 inhibitors, GLP-1 receptor agonists, and dual GIP/GLP-1 agonists provide complementary molecular mechanisms that improve insulin sensitivity, adiposity distribution, and cardiometabolic outcomes, though AA representation in trials remains limited. Novel approaches targeting circadian biology, the gut microbiome, and bariatric surgery further highlight the multifactorial pathogenesis of IR. Collectively, evidence supports a multimodal, individualized framework integrating lifestyle and pharmacologic therapies to equitably address insulin resistance in African American populations.

AA – African American

AMPK – AMP-activated protein kinase

BMI – Body mass index

BMR – Basal metabolic rate

C/EBP – CCAAT/enhancer-binding protein

CI – Confidence interval

DPP-4 – Dipeptidyl peptidase-4

FMT – Fecal microbiota transplantation

GIP – Glucose-dependent insulinotropic polypeptide

GLP-1 – Glucagon-like peptide-1

GLP-1RA – Glucagon-like peptide-1 receptor agonist

GLUT4 – Glucose transporter type 4

HbA1c – Hemoglobin A1c

HOMA-IR – Homeostatic model assessment of insulin resistance

HR – Hazard ratio

IKKβ – IκB kinase beta

IR – Insulin resistance

JNK – c-Jun N-terminal kinase

MACE – Major adverse cardiovascular event

NF-κB – Nuclear factor kappa-light-chain-enhancer of activated B cells

PROPEL – Promoting Successful Weight Loss in Primary Care in Louisiana

PPAR – Peroxisome proliferator-activated receptor

PPARγ – Peroxisome proliferator-activated receptor gamma

RCT – Randomized controlled trial

RYGB – Roux-en-Y gastric bypass

T2DM – Type 2 diabetes mellitus

TZD – Thiazolidinedione

UCP – Uncoupling protein

VLCDs – Very-low-calorie diets

VSG – Vertical sleeve gastrectomy

Insulin resistance (IR) is a central pathophysiologic process underlying obesity-related metabolic disease. Disruption of insulin signaling initiates a cascade of compensatory and maladaptive responses across metabolic, inflammatory, and cellular stress pathways, ultimately contributing to multisystem dysfunction. As a result, IR represents a major and growing public health challenge worldwide. According to the World Obesity Federation Obesity Atlas 2025, global obesity prevalence is projected to reach approximately 17% among men and 22% among women by 2030, corresponding to nearly 3 billion adults. In addition, nearly half of the world’s adult population is expected to have a body mass index (BMI) ≥25 kg/m² [1].

In the United States, obesity is defined as a BMI ≥30 kg/m² and currently affects approximately 38.4% of adult men and 41.3% of adult women [1,2]. Importantly, the metabolic consequences of IR are not uniformly distributed across populations. Data from the Centers for Disease Control and Prevention indicate that in 2024, non-Hispanic Black or AA adults experienced a 24% higher prevalence of diagnosed diabetes compared with the overall U.S. population. In 2021, rates of diabetes-related end-stage renal disease in this population were 2.19-fold higher than the national average, and by 2022 diabetes-attributable mortality exceeded that of the general population by approximately 40% [3,4]. These disparities reflect the complex interplay of biological susceptibility, environmental exposures, social determinants of health, and structural inequities, underscoring the need for population-specific investigation into the mechanisms and reversibility of IR [5]. This review aims to synthesize contemporary evidence on strategies to reverse insulin resistance (IR), with particular emphasis on African American populations disproportionately affected by IR. It evaluates biological, lifestyle, and therapeutic interventions to inform integrated approaches for reducing obesity-associated IR and its metabolic complications.

This narrative review synthesizes contemporary evidence on strategies to reverse insulin resistance with deliberate emphasis on populations of African descent, particularly African Americans. A structured literature search was conducted using PubMed/MEDLINE, and Google Scholar for peer-reviewed publications from 2000 through 2026. Search terms included combinations of insulin resistance, obesity, African American, health disparities, diet, exercise, lifestyle intervention, weight loss, pharmacotherapy, GLP-1 receptor agonist, SGLT2 inhibitor, thiazolidinedione, metformin, tirzepatide, microbiome, fecal microbiota transplantation, and bariatric surgery.

Eligible sources included RCTs, meta-analyses, systematic reviews, prospective cohort studies, and mechanistic investigations evaluating interventions that improve insulin sensitivity directly or indirectly. Studies reporting race-stratified outcomes, subgroup analyses including AA participants, or trials conducted in predominantly AA populations were prioritized. When AA-specific data were limited, broader findings were included and interpreted within the context of documented metabolic disparities. 

Evidence was appraised qualitatively based on study design, duration, population composition, insulin sensitivity metrics (e.g., HOMA-IR, euglycemic clamp), weight and adiposity outcomes, cardiovascular endpoints, safety profiles, and translational feasibility. Findings were synthesized into four thematic domains: (1) dietary interventions, (2) combined lifestyle and behavioral strategies, (3) pharmacologic therapies, and (4) emerging biologic and mechanistic approaches. This framework was used to evaluate both overall efficacy and population-specific applicability in addressing insulin resistance among African Americans.

Origins of Lifestyle Influences on Insulin Resistance

The search for effective strategies to reverse obesity and IR often colloquially framed as the search for a “cure” for weight gain, has spanned decades. Efforts to address this issue have been driven not only by the desire to improve health and longevity but also by the social and psychological consequences associated with obesity. Historically, the responsibility for preventing obesity and its metabolic consequences has largely been attributed to individual behavior. This perspective stems from early epidemiologic work suggesting that adherence to specific lifestyle habits could significantly influence long-term health outcomes. One of the earliest influential studies was conducted by Belloc and Breslow in the 1970s, who identified what they termed “seven health habits” associated with improved health outcomes and reduced obesity risk [6]. These habits included regular breakfast consumption, eating three meals daily without frequent snacking, participation in physical activity, maintaining a healthy body weight, adequate sleep, limited alcohol intake, and avoidance of smoking [6,7]. Their findings suggested that adherence to these behaviors was associated with improved metabolic health and lower rates of obesity, establishing a framework that influenced public health recommendations for decades.

Subsequent research refined these early observations. For example, Shigeta and colleagues expanded on these principles by directly examining their relationship with IR using glucose tolerance testing [7]. Their findings suggested that additional lifestyle factors, such as the speed of eating, regularity of meals, and sleep duration, may significantly influence metabolic outcomes. Specifically, individuals who ate quickly demonstrated a 1.5–1.8-fold increased likelihood of developing IR. Similarly, deviations from the traditional pattern of three meals per day were associated with increased metabolic risk. Sleep duration also emerged as an important determinant, with individuals sleeping fewer than six hours per night or regularly going to bed after midnight showing a significantly increased risk of developing IR [7].

These findings reinforced the importance of caloric moderation and physical activity but also highlighted that lifestyle determinants of IR are more complex than initially appreciated. Although early studies emphasized individual responsibility for obesity and metabolic disease, they also laid the foundation for a broader understanding of how behavioral patterns interact with metabolic physiology. Subsequent research has therefore focused on refining the specific contributions of diet, physical activity, and daily behavioral patterns to the development and reversal of metabolic disorders.

Dietary Interventions and Insulin Resistance

Dietary modification remains a central strategy in the management and reversal of IR. Numerous dietary approaches exist, and their effectiveness often depends on individual metabolic characteristics, lifestyle factors, and environmental constraints. One of the most widely studied approaches is caloric restriction, which promotes weight loss by creating a negative energy balance through reduced caloric intake and increased energy expenditure [8,9]. Within this framework, several variations exist. Low-calorie diets typically restrict daily caloric intake to approximately 1,000–1,500 kcal, whereas very-low-calorie diets (VLCDs) restrict intake to fewer than 800 kcal per day, often combined with carbohydrate intake below 30–50 g per day and protein consumption of approximately 0.8–1.2 g/kg of ideal body weight [8,9]. VLCDs, particularly when combined with structured meal replacements, have demonstrated the ability to induce significant weight loss and, in some cases, sustained improvements in IR for up to two years [9,10]. However, these diets are generally reserved for individuals with severe obesity due to their restrictive nature and the need for medical supervision [8-11].

Although these dietary approaches can be effective, their long-term success often depends on sustained adherence. Weight loss frequently occurs gradually and may require concurrent physical activity to maintain metabolic improvements. Additionally, compensatory reductions in energy expenditure may occur during prolonged caloric restrictions, potentially limiting long-term weight loss [8-11]. Beyond caloric restriction, several macronutrient-focused dietary strategies have been investigated. Low-fat diets typically limit fat intake to 10–30% of daily caloric consumption, whereas low-carbohydrate diets restrict carbohydrate intake to varying degrees. Ketogenic diets represent the most restrictive form, limiting carbohydrate intake to fewer than 50 g per day, while more moderate low-carbohydrate diets allow 50–130 g daily [8-11]. High-protein diets, which increase protein intake to approximately 0.8 g/kg or higher, have also been proposed as a strategy for promoting satiety and preserving lean body mass during weight loss [8-11].

Several regional dietary patterns have also been studied for their metabolic effects. The Mediterranean diet emphasizes high consumption of fruits, vegetables, fish, olive oil, and dairy products, whereas the Nordic diet focuses on whole grains, high-fiber foods, lean meats, and low-fat dairy. The Paleolithic diet emphasizes macronutrient distribution of approximately 30% protein, 35?rbohydrates, and 35?ts while excluding grains, dairy products, and processed foods [8-11]. Interestingly, emerging research has also explored the metabolic effects of dietary components beyond macronutrients. Certain herbs and spices, including cinnamon, garlic, amla, fenugreek, dill, and black cumin, have been associated with reductions in total cholesterol and low-density lipoprotein (LDL) levels. Garlic supplementation in particular has been associated with reductions in total cholesterol of approximately 10–33 mg/dL and LDL cholesterol reductions of 10–35 mg/dL [12]. These findings suggest that not only macronutrient composition but also micronutrients and bioactive compounds may influence metabolic outcomes.

Despite the wide range of dietary strategies available, long-term comparative studies suggest that differences in weight loss between diets often diminish over time. After approximately 24 months, weight-loss outcomes are largely determined by adherence rather than the specific dietary composition [9]. Consequently, selecting a dietary strategy that aligns with an individual's lifestyle and preferences may be the most important factor in long-term success. Importantly, relatively few studies have specifically examined dietary interventions in AA populations. Among the available studies, low-glycemic (low-carbohydrate) diets have shown promise when compared with high-glycemic, low-fat diets in improving weight loss and insulin sensitivity [13,14]. For example, Racette and colleagues demonstrated that dietary modification combined with lifestyle interventions produced moderate improvements in IR among obese AA participants after one year [15].

Another study involving AA and Latino adolescents evaluated the effects of reduced sugar intake and increased fiber consumption, with or without strength training, on metabolic outcomes over a 16-week period. Participants in the dietary intervention group showed improvements in glucose and insulin indices compared with controls, although increases in total fat mass and two-hour glucose levels were also observed [16]. These findings highlight the complexity of metabolic responses and suggest that racial and ethnic differences may influence intervention outcomes. More recently, the concept of personalized nutrition has emerged as a promising strategy. Personalized nutrition aims to tailor dietary interventions to an individual's genetic profile, metabolic characteristics, and lifestyle factors, thereby optimizing dietary responses and improving long-term adherence [17,18]. In practice, dietary interventions are rarely implemented in isolation and are frequently combined with physical activity to maximize metabolic benefits. The following section examines the role of exercise and lifestyle modification in reversing IR.

Fitness Routines and Lifestyle Changes in Reversing Insulin Resistance

Dietary modification alone has been insufficient to prevent the global rise in obesity or to achieve sustained reversal of IR. The reasons for this limitation remain an area of ongoing investigation. Current evidence suggests that the most effective strategies for reversing IR combine caloric restriction with increased energy expenditure through structured physical activity [19]. Whereas dietary interventions promote metabolic improvement primarily through the creation of a sustained negative energy balance, physical exercise improves insulin sensitivity through multiple cellular and molecular mechanisms. Exercise reduces inflammatory signaling through inhibition of microglial activation and decreased phosphorylation of stress-related pathways including JNK and IKKβ/NF-κB. It also reduces reactive oxygen species, alleviates endoplasmic reticulum stress, improves mitochondrial quality, and activates AMP-activated protein kinase (AMPK), which promotes autophagy and the clearance of misfolded proteins and other potentially harmful cellular components [20].

Early investigations into the combined effects of diet and exercise emerged from studies conducted between the 1970s and 1990s. The Oslo Diet–Heart Study and subsequent work by Torjesen and colleagues paired the Oslo diet, which emphasizes fish consumption and reduced dietary fat, with supervised endurance exercise performed three times weekly for one year [21,22]. Participants demonstrated reductions in IR alongside improvements in fasting insulin, glucose, and lipid levels. IR decreased from 5.0 to 4.0 during the intervention period, although exercise alone did not produce a statistically significant reduction in IR in that cohort [22]. Subsequent studies using more precise measurements of insulin sensitivity have demonstrated clearer benefits of exercise. Investigations utilizing the euglycemic hyperinsulinemic clamp technique found that modest aerobic exercise improved insulin sensitivity by approximately 1% (P = 0.23), while moderate aerobic exercise combined with increased fiber intake improved sensitivity by 9% (P = 0.94). In contrast, high-intensity aerobic exercise produced substantially greater improvements, with insulin sensitivity increasing by 23% (P = 0.006), and by 11% (P = 0.02) when combined with increased dietary fiber intake [23].

Evidence from systematic reviews further supports the importance of combining lifestyle strategies. A meta-analysis comparing dietary interventions alone with comprehensive behavioral weight-management programs found that outcomes were similar in short-term interventions, but programs lasting longer than 12 months demonstrated substantially greater weight-loss success when behavioral and lifestyle components were integrated [24]. A 2024 analysis of fourteen RCTs evaluating combined diet and exercise programs lasting at least 13 weeks reported a mean weight loss of −2.70 kg (95% CI, −3.69 to −1.71). Programs lasting 13–26 weeks produced a mean weight loss of −2.40 kg (95% CI, −4.44 to −0.37) [25]. These findings highlight the importance of sustained engagement, feasibility, and long-term adherence to lifestyle interventions.

Longitudinal epidemiologic data further emphasizes the preventive potential of lifestyle modification. Over a 10-year period, adults aged 36–79 years (mean age 54.5 ± 0.2 years) experienced an average weight gain of 4.2 ± 0.2 kg, representing approximately 6.6 ± 0.2% of baseline body weight. This corresponds to an annual weight gain of approximately 0.42 ± 0.02 kg per year, substantially lower than the weight reductions typically achieved through structured diet and exercise programs [26]. These findings suggest that sustained lifestyle interventions have the potential not only to reverse IR but also to prevent long-term weight gain. However, disparities in weight-gain trajectories have been observed across racial and ethnic groups. The same study reported that non-Hispanic Black participants experienced a greater mean weight gain of 6.3 ± 0.3 kg, representing 9.3 ± 0.3% of baseline body weight for both men and women [26]. These findings underscore the need to better understand how combined dietary and physical-activity interventions affect individuals of African descent and whether tailored strategies are necessary to optimize outcomes in these populations [27].

One study examining this question was the Promoting Successful Weight Loss in Primary Care in Louisiana (PROPEL) trial, which evaluated lifestyle interventions for weight loss in underserved, racially diverse populations, including African Americans. This study specifically assessed high-intensity behavioral interventions defined as at least 14 sessions over six months delivered by trained interventionists or primary-care providers [28]. Participants engaged in weekly sessions during the first six months followed by monthly sessions for the remaining 18 months. After 24 months, participants in the intensive lifestyle-intervention group achieved significantly greater weight loss (−4.99%; 95% CI, −6.02 to −3.96) compared with those receiving usual care (−0.48%; 95% CI, −1.57 to 0.61) [29].  Similarly, the Look AHEAD Study provided important evidence regarding lifestyle interventions that could promote weight loss and improve insulin sensitivity in overweight or obese individuals with Type 2 Diabetes [30]. The intervention combined increased physical activity (≥175 minutes per week of moderate exercise) with a reduced-calorie diet consisting of <30>

Collectively, these studies highlight the importance of physical activity as a critical adjunct to dietary interventions for reversing IR. However, the effectiveness of these strategies depends heavily on sustained adherence, consistency, and sufficient duration of intervention. Time constraints and the challenges associated with maintaining intensive lifestyle programs have led many individuals to seek additional therapeutic strategies to augment the metabolic benefits of diet and exercise [32]. The following section examines pharmacological approaches that may work synergistically with lifestyle interventions to reduce obesity and improve insulin sensitivity.

Biomolecular Approaches to Reducing Insulin Resistance

The search for pharmacologic therapies capable of producing sustained weight loss and improving insulin sensitivity comparable to long-term lifestyle interventions has been ongoing for decades. Such therapies are sought not only to reverse obesity-related metabolic dysfunction but also to prevent the progression to type 2 diabetes in high-risk individuals. Although no pharmacologic agent can fully eliminate obesity or IR on its own, several drug classes have demonstrated clinically meaningful improvements in insulin sensitivity when used alongside lifestyle interventions. Commonly used pharmacologic agents include biguanides, thiazolidinediones (TZDs) dipeptidyl peptidase-4 (DPP-4) inhibitors, sulfonylureas, peroxisome proliferator-activated receptor-γ (PPARγ) agonists, and glucagon-like peptide-1 receptor agonists (GLP-1RAs) [33,34]. These medications improve metabolic regulation through a variety of mechanisms, including increased insulin receptor signaling, enhanced glycogen synthesis, increased recruitment of glucose transporter-4 (GLUT-4) proteins, modulation of PPARα/δ/γ activity, and prolongation of GLP-1 activity through inhibition of DPP-4, collectively resulting in improved insulin sensitivity in hepatic and peripheral tissues [33,34]. Several additional agents have historically been used to promote weight loss through appetite suppression. These include sympathomimetic agents such as phentermine and amphetamine derivatives, as well as medications that influence central neurotransmitter pathways, including sibutramine, lorcaserin, and bupropion. However, these therapies are generally not considered first-line treatments due to limited long-term efficacy and increased risk of adverse effects [34]. Research into anti-inflammatory therapies has also suggested potential metabolic benefits. In vitro studies have demonstrated that high doses of salicylates can improve insulin sensitivity through inhibition of inflammatory signaling pathways involving IκB kinase β (IKKβ), which has been implicated in the development of IR [35].

Recent research has further refined our understanding of adiposity and metabolic risk. Evidence suggests that fat distribution, particularly increased visceral or abdominal adiposity, is more strongly associated with IR than overall body fat mass [36]. Consequently, investigators have examined whether pharmacologic agents can alter fat distribution in ways that reduce metabolic risk. TZDs promote adipogenesis through activation of PPARγ, often resulting in modest weight gain but with preferential redistribution of fat toward the gluteal–femoral regions and relatively neutral or reduced visceral fat accumulation [36]. In contrast, metformin suppresses adipogenesis and enhances mitochondrial fatty-acid oxidation through upregulation of uncoupling proteins (UCP1 and UCP3), leading to modest weight loss and reductions in visceral adiposity in patients with type 2 diabetes [36,37]. GLP-1 receptor agonists improve insulin sensitivity through several mechanisms, including enhanced glucose-dependent insulin secretion, suppression of adipogenic signaling pathways (PPARγ, C/EBPβ/δ, and AKT), increased lipolysis, and greater energy expenditure. Clinically, these agents produce significant reductions in both total body weight and visceral adiposity [36]. Similarly, sodium–glucose cotransporter-2 (SGLT2) inhibitors reduce renal glucose reabsorption, producing glycosuria and caloric loss that contribute to modest reductions in body weight and visceral fat [36,38]. Insulin therapy, although essential for glycemic control in advanced disease, is frequently associated with weight gain primarily through increased subcutaneous fat deposition. Sulfonylureas also promote insulin secretion and may contribute to weight gain, although their effects on fat distribution remain incompletely characterized [36, 39]. Despite the widespread use of these therapies, relatively few studies have specifically evaluated their safety and efficacy in AA populations. Available evidence suggests that several agents, including linagliptin, sibutramine, rosiglitazone, and metformin, demonstrate similar safety profiles in AA and Caucasian populations. Notably, some studies indicate that AA patients may experience a greater glycemic response to metformin therapy [40–43]. 

No contemporary discussion of pharmacologic therapy would be complete without addressing the rapid rise of GLP-1 receptor agonists and related incretin-based therapies. Since the approval of the first GLP-1RA, exenatide, in 2005 for the treatment of type 2 diabetes, newer agents including dulaglutide, semaglutide, and tirzepatide have become widely used for both glycemic control and weight management [44]. Beyond their effects on glucose regulation, these medications have demonstrated reductions in blood pressure, systemic inflammation, and postprandial lipemia. These benefits have translated into lower rates of heart failure, MACE’s, and chronic kidney disease in clinical trials [44]. The favorable safety profile of these medications has contributed to their widespread adoption. Most adverse effects are gastrointestinal and include nausea, diarrhea, constipation, and vomiting. Less common complications include gallbladder-related disorders such as cholecystitis, cholelithiasis, and biliary obstruction, occasionally requiring cholecystectomy [44].

Although current data suggest that GLP-1–based therapies are safe and effective across diverse populations, AA have historically been underrepresented in clinical trials, often comprising only approximately 9% of study participants [45,46]. Trials evaluating tirzepatide, a dual glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist, have demonstrated substantial improvements in glycemic control and body weight with minimal risk of hypoglycemia, although gastrointestinal side effects remain the most common adverse events [47]. A recent meta-analysis by Hasebe and colleagues evaluated race-stratified cardiovascular outcomes across nine trials, including the SOUL trial. The study reported reductions in MACE’s among Asian populations (HR 0.73; 95% CI 0.63–0.85; P < 0 xss=removed>

Novel Findings and Emerging Approaches to Reducing Insulin Resistance

Recent research suggests that long-term changes in population metabolic physiology may partially contribute to the rising prevalence of obesity and IR. Several modern analyses report a gradual decline in basal metabolic rate (BMR) over the past three decades, resulting in reduced basal energy expenditure despite relatively stable activity-related energy expenditure [50,51]. This decline in metabolic rate has been proposed as a potential contributor to the increasing global incidence of obesity and metabolic syndrome. A recent meta-analysis suggests that dietary composition may partially explain this trend, particularly shifts in fatty-acid intake. Reduced consumption of saturated fatty acids and increased prioritization of unsaturated fatty acids have been associated with alterations in metabolic rate, findings supported by experimental in vivo models [50,51]. Additionally, declining dietary fiber intake over time has been implicated as another contributing factor. Controlled trials have demonstrated that increased fiber consumption can positively influence metabolic rate and metabolic efficiency, suggesting that reductions in fiber intake may contribute to decreased basal energy expenditure at the population level [50-52].

Complementary investigations evaluating daily energy expenditure in economically developed nations have produced similar findings. These studies report that activity-related energy expenditure has not significantly declined over time, suggesting that reductions in physical activity alone may not fully explain rising obesity prevalence. Instead, dietary factors appear to play a more substantial role, with total energy expenditure accounting for only a modest proportion of variability in body mass index (BMI) and body fat index in developed populations [53]. Given the difficulty of maintaining long-term dietary restriction and sustained physical activity, researchers have increasingly explored alternative approaches that may help prevent or reverse obesity and IR. One emerging area of investigation involves circadian rhythm regulation. Oosterman and colleagues demonstrated that individuals living out of sync with endogenous circadian rhythms exhibit disrupted organ-level metabolic coordination, leading to dysregulation of glucose homeostasis. These findings have been supported by in vivo animal models and epidemiologic observations showing increased metabolic dysfunction among individuals with shift-work schedules or irregular sleep–wake cycles [54].

Another rapidly evolving area of research involves the role of the gastrointestinal microbiome in metabolic regulation. Evidence suggests that microbial composition may influence susceptibility to both the development and reversal of IR [55-57]. Clinical studies evaluating fecal microbiota transplantation (FMT) in individuals with type 2 diabetes have demonstrated improvements in metabolic markers including HOMA-IR, BMI, fasting glucose, postprandial glucose, and HbA1c. Notably, these improvements appear to be enhanced when FMT is combined with metformin therapy and have been observed within weeks following transplantation without significant adverse effects such as hypoglycemia or dyslipidemia [55-57]. Further microbial analyses have identified specific organisms associated with improved insulin sensitivity, including Chlorobium phaeovibrioides, Bifidobacterium adolescentis, and Synechococcus sp. WH8103. In contrast, organisms such as Lactobacillus ruminis, Dysosmobacter welbionis, and Xylanimicrobium sp. FW10M-9 have been positively correlated with insulin-resistant metabolic states [55-57]. These findings further emphasize the potential importance of microbiome composition in metabolic regulation.

For individuals with severe obesity in whom lifestyle interventions are insufficient, metabolic surgery remains one of the most effective therapeutic options. Procedures such as vertical sleeve gastrectomy (VSG) and Roux-en-Y gastric bypass (RYGB) have demonstrated significant improvements in insulin sensitivity and metabolic regulation. When combined with dietary lipid restriction, these procedures have been associated with restoration of GLUT4 expression, normalization of leptin signaling, and reductions in intramyocellular lipid accumulation [58,59]. Similar to microbiome-directed therapies, the metabolic benefits of bariatric surgery are thought to arise in part from alterations in gut anatomy, hormonal signaling, and microbiota composition, which collectively modify gut–brain communication and temporarily reset the body’s metabolic set point [59]. Collectively, these emerging findings highlight the multifactorial nature of IR and underscore the importance of integrated therapeutic strategies that address metabolic regulation at behavioral, physiologic, and microbial levels [55-59].

Insulin resistance represents a fundamental metabolic defect linking obesity, type 2 diabetes mellitus, and broader cardiometabolic disease. In the United States, African American populations experience a disproportionate burden of these conditions, reflecting a complex interplay of biologic susceptibility, environmental exposures, and structural inequities [60-63]. Despite this disparity, African American individuals remain underrepresented in studies evaluating emerging metabolic therapies, limiting the generalizability and translational applicability of current treatment strategies [60-63]. Chronic psychosocial stressors, inequitable access to healthcare resources, and insufficient policy-level interventions further exacerbate these disparities. As illustrated in Figure 1, insulin resistance is best conceptualized as a central node within a network of interacting determinants, where sustained improvement requires coordinated, multidomain intervention rather than reliance on a single strategy.

Emerging approaches including microbiome modulation, circadian rhythm alignment, and metabolic surgery further emphasize the complex, systems-level regulation of insulin sensitivity and the importance of the gut–brain–adipose axis. Within this evolving framework, Sirtuin 1(SIRT1) has been identified as a potential molecular mediator linking environmental and behavioral exposures to metabolic regulation [64-66]. SIRT1 activity is influenced by modifiable factors such as diet, physical activity, sleep, and psychosocial stress, suggesting a biologically plausible mechanism through which social and lifestyle determinants may contribute to insulin resistance, particularly in African American populations [64-66].

Future research should prioritize mechanistic and translational studies evaluating SIRT1 as both a biomarker and therapeutic target, including early-life assessment of SIRT1 levels and investigation of dietary or pharmacologic modulators of its activity. More broadly, adequately powered, race-stratified clinical trials are needed to define treatment efficacy, safety, and metabolic outcomes in African American populations. Addressing these gaps, alongside culturally informed and equity-focused implementation strategies, will be essential for advancing precision-based interventions and reducing disparities in insulin resistance and cardiometabolic disease.

 Figure 1: Systems-level model of insulin resistance reversal: This model illustrates insulin resistance as the central node within a network of interacting lifestyle, pharmacologic, biologic, and environmental determinants. Effective reversal of IR requires coordinated interventions across multiple domains, including circadian-aligned behavioral patterns, sustained physical activity, personalized dietary strategies, targeted pharmacotherapy (e.g., GLP-1–based therapies), and emerging interventions such as microbiome modulation. The framework emphasizes that meaningful improvement in insulin sensitivity is most likely achieved through integrated, multimodal strategies rather than reliance on a single therapeutic approach.

Reversal and sustained attenuation of insulin resistance require an integrated, individualized approach that combines lifestyle modification, pharmacologic therapy, and emerging biologic strategies. Policies that improve equitable access to healthy food environments, safe spaces for physical activity, preventive healthcare services, and community-based behavioral programs while reducing socioeconomic stressors and healthcare access barriers, are essential for translating clinical advances into population-level impact. Advancing mechanism-driven, equity-focused strategies that integrate clinical innovation with structural and policy reform will be critical to meaningfully reduce the burden of insulin resistance and cardiometabolic disease in African American communities.

Authors’ Contributions:

Dr. Kanwal K. Gambhir conceived the idea and finalized the manuscript; Victor D. Ellis III drafted the first draft including all figure. Dr. Maurice B Fluitt edited the prefinal draft.